ADC Therapeutics SA Income Statement
ADCT|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
ADC Therapeutics SA reported $81M in revenue and $143M in net loss for FY2025. Revenue has declined at a 37.7% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.83 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $81.4M | $69.6M | $209.9M |
| Cost of Revenue | $5.8M | $2.5M | $3.3M |
| SG&A Expense | $36.6M | $48.4M | $74.4M |
| R&D Expense | $104.0M | $127.1M | $186.5M |
| Operating Income | -$121.5M | -$166.0M | -$123.3M |
| Interest Expense | $16.3M | $46.3M | $36.7M |
| Income Tax | $1.0M | $39.1M | $227.0K |
| Net Income | -$142.6M | -$240.1M | -$157.1M |
| EPS (Basic) | -$1.62 | -$2.94 | -$2.01 |
| EPS (Diluted) | -$1.62 | -$2.94 | -$2.01 |
| Shares Outstanding | 98.9M | 82.3M | 80.6M |
| Operating Margin | -149.3% | -238.6% | -58.8% |
| Profit Margin | -175.3% | -345.1% | -74.9% |